Mereo BioPharma Group plc shareholders approved Authorization to allot shares for cash on non-pre-emptive basis at the 2026-05-14 meeting.
“Resolution 11 That, subject to Resolution 10 being passed, the Directors are authorized to allot shares for cash on a non-pre-emptive basis up to a maximum nominal amount of £3,591,354.73. The authority set out in Resolution 11 will expire on June 30, 2029. Vote for % of shares voted Votes against % of shares voted Votes withheld 254,938,500 80.59% 61,391,160 19.41% 120,436,595”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Authorization to allot shares at the 2026-05-14 meeting.
“Resolution 10 That the Directors are authorized in accordance with section 551 of the Companies Act 2006 to allot shares in the Company and to grant rights to subscribe for or convert any security into shares in the Company up to a maximum nominal amount of £3,591,354.73. The authority set out in Resolution 10 will expire on June 30, 2029 and would replace the existing authority granted at the general meeting of the Company held on May 22, 2023 to the extent not utilized at the date this Resolution is passed. Vote for % of shares voted Votes against % of shares voted Votes withheld 254,728,730 80.54% 61,529,760 19.46% 120,507,765”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Re-election of directors at the 2026-05-14 meeting.
“Resolution 7 That Justin Roberts be re-appointed as a director of the Company. Vote for % of shares voted Votes against % of shares voted Votes withheld 295,886,535 93.77% 19,670,940 6.23% 121,208,780 Resolution 8 That Dr. Daniel Shames be re-appointed as a director of the Company. Vote for % of shares voted Votes against % of shares voted Votes withheld 297,469,530 94.27% 18,085,670 5.73% 121,211,055 Resolution 9 That Marc Yoskowitz be re-appointed as a director of the Company. Vote for % of shares voted Votes against % of shares voted Votes withheld 297,750,480 94.32% 17,929,525 5.68% 121,086,250”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-14 meeting.
“Resolution 6 That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis. Vote for % of shares voted Votes against % of shares voted Votes withheld 290,149,130 91.71% 26,223,920 8.29% 120,393,205”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Approval of directors' remuneration policy at the 2026-05-14 meeting.
“Resolution 5 That the directors’ remuneration policy as set out in the Company’s annual report and accounts for the year ended December 31, 2025, which takes effect from the end of the annual general meeting, be approved. Vote for % of shares voted Votes against % of shares voted Votes withheld 290,456,675 91.74% 26,150,725 8.26% 120,158,855”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Approval of directors' remuneration report at the 2026-05-14 meeting.
“Resolution 4 That the directors’ remuneration report (excluding the directors’ remuneration policy), as set out in the Company’s annual report and accounts for the year ended December 31, 2025, be approved. Vote for % of shares voted Votes against % of shares voted Votes withheld 295,564,225 93.35% 21,038,465 6.65% 120,163,565”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Authorization of Audit and Risk Committee to determine auditors' remuneration at the 2026-05-14 meeting.
“Resolution 3 That the Audit and Risk Committee be authorized to determine PwC’s remuneration for the fiscal year ending December 31, 2026. Vote for % of shares voted Votes against % of shares voted Votes withheld 311,313,685 98.22% 5,656,600 1.78% 119,795,970”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Re-appointment of PricewaterhouseCoopers LLP as auditors at the 2026-05-14 meeting.
“Resolution 2 That PricewaterhouseCoopers LLP (“PwC”) be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company’s annual report and accounts are presented. Vote for % of shares voted Votes against % of shares voted Votes withheld 429,804,470 98.59% 6,156,620 1.41% 805,165”
Shareholder Votes
Mereo BioPharma Group plc shareholders approved Adoption of annual report and accounts at the 2026-05-14 meeting.
“Resolution 1 That the annual report and accounts for the year ended December 31, 2025, together with the directors’ report and independent auditor’s report thereon, be received and adopted. Vote for % of shares voted Votes against % of shares voted Votes withheld 311,388,645 98.29% 5,412,060 1.71% 119,965,550”
Earnings Releases
Mereo BioPharma Group plc reported first quarter ended March 31, 2026 results: net income $6.7 million. Guidance reaffirmed.
“Net loss for the first quarter of 2026 was $6.7 million”
Earnings Releases
Mereo BioPharma Group plc reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $6.7 million.
“On May 12, 2026, Mereo BioPharma Group plc announced its financial results for the first quarter ended March 31, 2026 and provided an update on recent corporate developments.”
Earnings Releases
Mereo BioPharma Group plc reported financial results for the full year ended December 31, 2025.
“Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments.”
Listing & Compliance Notices
Mereo BioPharma Group plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a letter (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its American Depositary Shares (“ADSs”) failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notification Letter does not result in the immediate delisting of the Company’s ADSs, and the ADSs will contin”
Material Agreements
Mereo BioPharma Group plc entered into Extension Letter to Cooperation Agreement with Rubric Capital Management L.P. valued at Extension Letter waiving resignation requirement and extending termination date to after 2025 annual (effective 2024-04-15).
“On April 15, 2024, Mereo BioPharma Group plc (the “Company”) entered into an extension letter, effective as of April 15, 2024 (the “Extension Letter”) to the cooperation agreement, dated October 28, 2022 (the “Cooperation Agreement”), between the Company and Rubric Capital Management L.P. (“Rubric Capital”).”
Earnings Releases
Mereo BioPharma Group plc reported financial results for the year ended December 31, 2023.
“On March 27, 2024, Mereo BioPharma Group plc announced its financial results for the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.